Refine
Year of publication
Document Type
- Article (51)
- Preprint (5)
- Conference Proceeding (4)
- Review (1)
Has Fulltext
- yes (61)
Is part of the Bibliography
- no (61)
Keywords
- SARS-CoV-2 (7)
- COVID-19 (6)
- Medizinstudenten (4)
- PCR (4)
- medical students (4)
- ELISA (3)
- antiviral therapy (3)
- occupational infections (3)
- Blutübertragbare Virusinfektionen (2)
- IFT (2)
- Immunenzymtechniken (2)
- Immunoenzyme Techniques (2)
- Impfraten (2)
- Labordiagnostik (2)
- Nadelstichverletzungen (2)
- PRNT (2)
- Virussicherheit (2)
- antiviral drugs (2)
- blood borne infection (2)
- bloodborne viruses (2)
- blutübertragbare Infektionskrankheiten (2)
- needlestick injury (2)
- vaccine uptake rates (2)
- Acute HIV infection (1)
- Ag-RDT (1)
- Akkreditierung (1)
- Anti-CMV IgG (1)
- Antigene Virale/Immunologie (1)
- Antigennachweis (1)
- Antigens,Viral/immunology (1)
- Atherosklerose (1)
- Automatisation (1)
- Autopsy (1)
- BNT162b2 (1)
- Bio safety (1)
- Blut- und Plasmaprodukte (1)
- Bone Gla Protein (1)
- Bovine Spongiforme Enzephalopathie (BSE) (1)
- Bovine spongiform, encephalopathy (BSE) (1)
- CMVepidemiology (1)
- Cell culture (1)
- ChAdOx1-S (1)
- Chlamydia-Infections/urine (1)
- Chlamydien (1)
- Chlamydieninfektionen/Urin (1)
- Congenital CMVinfection (1)
- Corona virus (1)
- Cytomegalie-Virus (1)
- Cytomegalovirus (1)
- Cytomegalovirus (CMV) (1)
- DIN EN ISO 15189 (1)
- Diagnose (1)
- Diagnosis (1)
- Diagnostik (1)
- Donor screening (1)
- EN ISO 15189 (1)
- Ebola (1)
- Epidemiologie (1)
- Erregernachweis (1)
- Genamplifikation (1)
- Gene-Amplification (1)
- Germany (1)
- HHV-8 (1)
- HIV (1)
- HSV (1)
- HSV type specific antibodies (1)
- HSV-1 (1)
- HSV-2 (1)
- HSV-typenspezifische Antikörper (1)
- Health care workers (1)
- Healthcare worker (1)
- Hepatitis C-Virus (HCV) (1)
- Hepatitis G virus (1)
- Hepatitis G-Virus (1)
- Herpe-Viren (1)
- Herpes Simplex Virus/isolation and purification . (1)
- Herpes simplex Virus/Isolierung und Anreicherung (1)
- Herpes virus (1)
- Heterologous prime-boost (1)
- Human immunodeficiency virus (HIV) (1)
- IFA (1)
- IgG (1)
- Immunogenicity (1)
- Immunosuppression (1)
- Immunsuppression (1)
- Inactivation (1)
- Influenza (1)
- KSHV epidemiology (1)
- KSHV, Epidemiologie (1)
- Knochenstoffwechselerkrankungen (1)
- Koronare Herzkrankheit (1)
- Laborpersonal (1)
- Lack of immunity (1)
- Mandatory Vaccinations (1)
- Medical history (1)
- Mikroneutralisationstest (1)
- Osteocalcin (1)
- Otorhinolaryngological (1)
- POCT (1)
- Pandemic (1)
- Plasmapools (1)
- Plasmapräparate (1)
- Poliomyelitis (1)
- Polioviren (1)
- Polymerase Kettenreaktion (PCR) (1)
- Qualitätsmanagement (1)
- RT-PCR-detection (1)
- Rapid diagnostic test (1)
- Reactogenicity (1)
- ReagentKits, -Diagnostic (1)
- Reagenzkits, Diagnostische (1)
- Respiratorische Infekte (1)
- SARS‐CoV‐2 (1)
- Screening-ELISA (1)
- Sensitivity and Specificity (1)
- Sensitivität und Spezifität (1)
- Seroconverter (1)
- Seroepidemiology (1)
- Serology (1)
- Seroprevalence (1)
- Speziesbarriere (1)
- Stability (1)
- T cell response (1)
- Urethra/Mikrobiologie (1)
- Urethra/microbiology (1)
- Vaccination (1)
- Vaccine uptake rate (1)
- Virological testing (1)
- Virologie (1)
- Virus infection (1)
- Virusinfektionen (1)
- Virusisolierung (1)
- Viruspneumonien (1)
- Vorbeugemaßnahmen (1)
- Western blot (1)
- accreditation (1)
- antibody tests (1)
- antigen detection (1)
- arbeitsbedingte Infektionen (1)
- atherosclerosis (1)
- automation (1)
- behördliche Anforderungen (1)
- blood- and plasma products (1)
- bone Gla protein (1)
- booster (1)
- cell culture (1)
- chelator (1)
- chlamydia (1)
- coronary heart disease (1)
- cytomegalovirus (1)
- demonstration of the infectious agent (1)
- diagnostic test (1)
- diagnostics (1)
- disorders of bone metabolism (1)
- drug repurposing (1)
- drug resistance (1)
- eltrombopag (1)
- enteral transmission (1)
- enterale Übertragung (1)
- epidemiology (1)
- healthcare personnel (1)
- healthcare worker (1)
- healthcare workers (1)
- hemodialysis (1)
- hepatitis C virus (HCV) (1)
- human cytomegalovirus (1)
- human prion diseases (1)
- infant (1)
- infectious diseases (1)
- infectivity (1)
- influenza (1)
- iron chelation (1)
- laboratory diagnostic (1)
- laboratory diagnostics (1)
- laboratory worker (1)
- mRNA-1273 (1)
- medizinische Beschäftigte (1)
- medizinisches Personal (1)
- menschliche Prionenerkrarikungen (1)
- microneutralization assay (1)
- monkeypox (1)
- neonate (1)
- neonatology (1)
- neurological impairment (1)
- neutralizing antibodies (1)
- newborn (1)
- newborn screening (1)
- official requirements (1)
- orthopoxvirus (1)
- pertussis (1)
- plasma pools and products (1)
- poliovirus (1)
- polymerase chain reaction (PCR) (1)
- poxvirus (1)
- precautions (1)
- proton pump inhibitors (1)
- quality management (1)
- respiratory infections (1)
- ribavirin (1)
- screening ELISA (1)
- seroconversion (1)
- species barrier (1)
- surrogate ELISA (1)
- thrombopietin receptor agonist (1)
- vaccination (1)
- vaccination rates (1)
- viral contamination (1)
- virology (1)
- virus isolation (1)
- virus pneumonia (1)
- virus-safety (1)
Institute
- Medizin (61)
- Georg-Speyer-Haus (1)
Background In October 2007, the working group CEN/TC 216 of the European Committee for standardisation suggested that the Sabin oral poliovirus vaccine type 1 strain (LSc-2ab) presently used for virucidal tests should be replaced by another attenuated vaccine poliovirus type 1 strain, CHAT. Both strains were historically used as oral vaccines, but the Sabin type 1 strain was acknowledged to be more attenuated. In Germany, vaccination against poliomyelitis was introduced in 1962 using the oral polio vaccine (OPV) containing Sabin strain LSc-2ab. The vaccination schedule was changed from OPV to an inactivated polio vaccine (IPV) containing wild polio virus type 1 strain Mahoney in 1998. In the present study, we assessed potential differences in neutralising antibody titres to Sabin and CHAT in persons with a history of either OPV, IPV, or OPV with IPV booster. Methods Neutralisation poliovirus antibodies against CHAT and Sabin 1 were measured in sera of 41 adults vaccinated with OPV. Additionally, sera from 28 children less than 10 years of age and immunised with IPV only were analysed. The neutralisation assay against poliovirus was performed according to WHO guidelines. Results The neutralisation activity against CHAT in adults with a complete OPV vaccination series was significantly lower than against Sabin poliovirus type 1 strains (Wilcoxon signed-rank test P < 0.025). In eight sera, the antibody titres measured against CHAT were less than 8, although the titre against Sabin 1 varied between 8 and 64. Following IPV booster, anti-CHAT antibodies increased rapidly in sera of CHAT-negative adults with OPV history. Sera from children with IPV history neutralised CHAT and Sabin 1 strains equally. Conclusion The lack of neutralising antibodies against the CHAT strain in persons vaccinated with OPV might be associated with an increased risk of reinfection with the CHAT polio virus type 1, and this implies a putative risk of transmission of the virus to polio-free communities. We strongly suggest that laboratory workers who were immunised with OPV receive a booster vaccination with IPV before handling CHAT in the laboratory.
Reliable, easy-to-handle phenotypic screening platforms are needed for the identification of anti-SARS-CoV-2 compounds. Here, we present caspase 3/7 activity as a read-out for monitoring the replication of SARS-CoV-2 isolates from different variants, including a remdesivir-resistant strain, and of other coronaviruses in a broad range of cell culture models, independently of cytopathogenic effect formation. Compared to other cell culture models, the Caco-2 subline Caco-2-F03 displayed superior performance, as it possesses a stable SARS-CoV-2 susceptible phenotype and does not produce false-positive hits due to drug-induced phospholipidosis. A proof-of-concept screen of 1796 kinase inhibitors identified known and novel antiviral drug candidates including inhibitors of PHGDH, CLK-1, and CSF1R. The activity of the PHGDH inhibitor NCT-503 was further increased in combination with the HK2 inhibitor 2-deoxy-D-glucose, which is in clinical development for COVID-19. In conclusion, caspase 3/7 activity detection in SARS-CoV-2-infected Caco-2F03 cells provides a simple phenotypic high-throughput screening platform for SARS-CoV-2 drug candidates that reduces false positive hits.
Reliable, easy-to-handle phenotypic screening platforms are needed for the identification of anti-SARS-CoV-2 compounds. Here, we present caspase 3/7 activity as a readout for monitoring the replication of SARS-CoV-2 isolates from different variants, including a remdesivir-resistant strain, and of other coronaviruses in numerous cell culture models, independently of cytopathogenic effect formation. Compared to other models, the Caco-2 subline Caco-2-F03 displayed superior performance. It possesses a stable SARS-CoV-2 susceptibility phenotype and does not produce false-positive hits due to drug-induced phospholipidosis. A proof-of-concept screen of 1,796 kinase inhibitors identified known and novel antiviral drug candidates including inhibitors of phosphoglycerate dehydrogenase (PHGDH), CDC like kinase 1 (CLK-1), and colony stimulating factor 1 receptor (CSF1R). The activity of the PHGDH inhibitor NCT-503 was further increased in combination with the hexokinase II (HK2) inhibitor 2-deoxy-D-glucose, which is in clinical development for COVID-19. In conclusion, caspase 3/7 activity detection in SARS-CoV-2-infected Caco-2-F03 cells provides a simple phenotypic high-throughput screening platform for SARS-CoV-2 drug candidates that reduces false-positive hits.
603 Seren aus dem Raum Frankfurt am Main wurden in 12 verschiedenen Einzelkollektiven mit einem "in house" IFT mit latenten Antigenen und einem rekombinanten Prototyp ELISA mit dem LANA und K8.1-Protein auf Antikörper gegen das Humane Herpesvirus Typ 8 (HHV-8) ± auch bekannt als Kaposi-Sarkom-assoziiertes Herpesvirus (KSHV) ±getestet. Untersucht wurden (Risiko)gruppen wie HIV-seropositive Männer und Frauen, HIV-seronegative homosexuelle bzw. bisexuelle Männer, Patienten mit Kaposi-Sarkom, Transplantationspatienten und Kinder mit Hämophilie. Zur Abschätzung von Kreuzreaktionenund anderen Störungen der Testsysteme wurden Patienten mit akuten bzw. abgelaufenen EBV-Infektionen,HHV-6-seropositive Patienten, Rheumafaktor-positive Probanden und Frauen mit primärer biliärer Zirrhose(PBC) untersucht. Dreiundfünfzig diskrepante Probenwurden mit kommerziellen IFTs mit latenten bzw. lyti-schen Antigenen nachgetestet.Hohe HHV-8-SeropraÈvalenzen wurden bei HIV-Infizierten ohne (15,7 % bei Frauen, 23,3 % bei Männern)und insbesondere mit Kaposi-Sarkomen (100 %) gefunden. Eine geschlechtsabhängige Verteilung der Seroprävalenz bei den HIV-seropositiven Patienten wurde nicht festgestellt. Bei Blutspendern wurde eine HHV-8-Durchseuchung von 3 % (im ¹in-house-IFTª), bei Hämophilen von 0 % und bei Transplantationspatienten von 9,1 % ermittelt. Kreuzreaktionen mit Antikörpern gegen andere Herpesviren wie EBV und HHV-6 schienen die Tests nicht zu beeinflussen, während sich tendenziell eine erhöhte Anzahl reaktiver Proben bei Patienten mit Autoimmunantikörpern (Rheumafaktor-positive Patienten und Patientinnen mit PBC) zeigte. Insgesamt stimmten die Ergebnisse des rekombinanten ELISA mit denen des "in house"-IFT im Gesamtkollektiv gut überein. Unterschiedliche Ergebnisse fanden sich in den Einzelkollektiven, insbesondere bei Rheumafaktor-positiven Patienten und solchen mit PBC.
Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes.
Methods: Individuals receiving either heterologous (ChAdOx1-S [AstraZeneca, Cambridge, UK]/BNT162b2 [Pfizer-BioNTech, Mainz, Germany]; n = 306) or homologous (messenger RNA [mRNA]-1273 [Moderna, Cambridge, Massachusetts, USA]; n = 139) vaccination were asked to participate when receiving their second dose. Reactogenicity was assessed after 1 month, immunogenicity after 1, 3, and/or 6 months, including a third dose, through SARS-CoV-2 antispike immunoglobulin G, surrogate virus neutralization test, and a plaque reduction neutralization test against the Delta (B.1.167.2) and Omicron (B.1.1.529; BA.1) variants of concern.
Results: The overall reactogenicity was lower after heterologous vaccination. In both cohorts, SARS-CoV-2 antispike immunoglobulin G concentrations waned over time with the heterologous vaccination demonstrating higher neutralizing activity than homologous mRNA vaccination after 3 months to low neutralizing levels in the Delta plaque reduction neutralization test after 6 months. At this point, 3.2% of the heterologous and 11.4% of the homologous cohort yielded low neutralizing activity against Omicron. After a third dose of an mRNA vaccine, ≥99% of vaccinees demonstrated positive neutralizing activity against Delta. Depending on the vaccination scheme and against Omicron, 60% to 87.5% of vaccinees demonstrated positive neutralizing activity.
Conclusion: ChAdOx1-S/BNT162b2 vaccination demonstrated an acceptable reactogenicity and immunogenicity profile. A third dose of an mRNA vaccine is necessary to maintain neutralizing activity against SARS-CoV-2. However, variants of concern-adapted versions of the vaccines would be desirable.
Background: Hundreds of West African healthcare workers (HCW) have become ill with Ebola virus disease (EVD) and died during the recent outbreak. The occurrence of occupational infections in laboratories could be due to the lack of use of personal protective equipment, the failure to implement specific regulations about the use of equipment and how to work with hazardous materials. Our study attempted to assess the information as well as training level of HCW of a German high level isolation unit and their concern over an occupationally acquired EVD.
Methods: During the recent Ebola virus outbreak a survey was conducted among HCWs, using an anonymous questionnaire.
Results: Although 70% of our total study population stated that they have all the information needed to care for Ebola patients, only 18.2% of laboratory workers and 29.4% of the HCW of the virology department felt sufficiently trained. The HCW rated the Internet (64.3%) and the daily press (54.3%) as the most important sources of information. Medical literature (45.7%) and official institutions (40.4%) were rated less often.
Conclusions: Formulated pointedly, the HCW turned to popular science to get the information they need to feel safe. Further in house training regarding practical skills and reference to scientific literature would be a better solution to ensure workplace safety.
In einer vernetzten Welt machen Epidemien nicht an Ländergrenzen Halt. Mit der zunehmenden Verfügbarkeit von wirksamen Therapien in Entwicklungsländern wird nun auch das Wissen, das in den Industrieländern durch klinische Forschung gewonnen wurde, für Afrika und Südost-Asien interessant. Das Wissen um eine verbesserte Behandlung HIV-Infizierter mit benachteiligten Regionen in Afrika zu teilen, ist auch das Anliegen einer Klinikpartnerschaft zwischen dem Frankfurter HIVCENTER und der Karabong Klinik des Mafeteng Government Hospitals in Lesotho. Durch die Einbeziehung der Universitätsklinik in Stellenbosch, Südafrika, die eine Hochschulpartnerschaft mit der Universitätsklinik Frankfurt unterhält, soll zudem der Süd-Süd-Austausch zwischen den afrikanischen Partnern gestärkt werden.
Im vorliegenden Fall wird von einer Fehldiagnose auf der Grundlage eines falsch-reaktiven Anti-HCV-Tests und eines falsch-reaktiven HCV-Nukleinsäureamplifikationstests (NAT) berichtet, die bei einem 58-jährigen chirurgischen Oberarzt im Rahmen einer arbeitsmedizinischen Vorsorgeuntersuchung im krankenhauseigenen Labor gestellt wurde und zu einem knapp zweimonatigen Berufsverbot führte. Basis dieser Fehldiagnose war ein wiederholt schwach reaktiver HCV-Antikörper-ELISA, der mit einem Nukleinsäureamplifikationstest, der ebenfalls schwach positiv ausfiel, überprüft wurde. Ein Antikörperbestätigungs- bzw. Ergänzungstest (Immunoblot) wurde nicht durchgeführt. Die Fehldiagnose ist jedoch nicht durch einen Testfehler, sondern durch ein Missverständnis entstanden, indem beim Kliniker zwei Laborindizien zu einem Beweis aufsummiert wurden.
Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
(2021)
The novel coronavirus SARS-CoV-2 is the causative agent of the acute respiratory disease COVID-19, which has become a global concern due to its rapid spread. Laboratory work with SARS-CoV-2 in a laboratory setting was rated to biosafety level 3 (BSL-3) biocontainment level. However, certain research applications in particular in molecular biology require incomplete denaturation of the proteins, which might cause safety issues handling contaminated samples. In this study, we evaluated lysis buffers that are commonly used in molecular biological laboratories for their ability to inactivate SARS-CoV-2. In addition, viral stability in cell culture media at 4 °C and on display glass and plastic surfaces used in laboratory environment was analyzed. Furthermore, we evaluated chemical and non-chemical inactivation methods including heat inactivation, UV-C light, addition of ethanol, acetone-methanol, and PFA, which might be used as a subsequent inactivation step in the case of insufficient inactivation. We infected susceptible Caco-2 and Vero cells with pre-treated SARS-CoV-2 and determined the tissue culture infection dose 50 (TCID50) using crystal violet staining and microscopy. In addition, lysates of infected cells and virus containing supernatant were subjected to RT-qPCR analysis. We have found that guanidine thiocyanate and most of the tested detergent containing lysis buffers were effective in inactivation of SARS-CoV-2, however, the M-PER lysis buffer containing a proprietary detergent failed to inactivate the virus. In conclusion, careful evaluation of the used inactivation methods is required especially for non-denaturing buffers. Additional inactivation steps might be necessary before removal of lysed viral samples from BSL-3.
Surface disinfectants are part of broader preventive strategies preventing the transmission of bacteria, fungi and viruses in medical institutions. To evaluate their virucidal efficacy, these products must be tested with appropriate model viruses with different physico-chemical properties under conditions representing practical application in hospitals.
The aim of this study was to evaluate a quantitative carrier assay. Furthermore, different putative model viruses like adenovirus type 5 (AdV-5) and different animal parvoviruses were evaluated with respect to their tenacity and practicability in laboratory handling. To evaluate the robustness of the method, some of the viruses were tested in parallel in different laboratories in a multi-center study. Different biocides, which are common active ingredients of surface disinfectants, were used in the test. After drying on stainless steel discs as the carrier, model viruses were exposed to different concentrations of three alcohols, peracetic acid (PAA) or glutaraldehyde (GDA), with a fixed exposure time of 5 minutes. Residual virus was determined after treatment by endpoint titration.
All parvoviruses exhibited a similar stability with respect to GDA, while AdV-5 was more susceptible. For PAA, the porcine parvovirus was more sensitive than the other parvoviruses, and again, AdV-5 presented a higher susceptibility than the parvoviruses. All parvoviruses were resistant to alcohols, while AdV-5 was only stable when treated with 2-propanol. The analysis of the results of the multi-center study showed a high reproducibility of this test system.
In conclusion, two viruses with different physico-chemical properties can be recommended as appropriate model viruses for the evaluation of the virucidal efficacy of surface disinfectants: AdV-5, which has a high clinical impact, and murine parvovirus (MVM) with the highest practicability among the parvoviruses tested.